TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30056548

Group type: EXPERIMENTAL
Intervention: Acute resistance exercise (RE)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Non-exercise control condition
Number of subjects: 35
Study: 26790360

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Health education (HE)
Number of subjects: 88
Study: 24801842

Group type: EXPERIMENTAL
Intervention: Vitamin E (18 mg, 27 IU) and Vitamin E acetate (27 mg, 27 IU) delivered via tube-feeding
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Vitamin E (18 mg, 27 IU) and Vitamin E acetate (27 mg, 27 IU)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cubic phase formulation
Number of subjects: 6
Study: 22281100

Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 20133508

Group type: EXPERIMENTAL
Intervention: Subcutaneous golimumab 50 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Subcutaneous golimumab 100 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Subcutaneous golimumab (both doses)
Number of subjects: 51
Study: 19019650

Group type: EXPERIMENTAL
Intervention: 10% HES
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 6% HES
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 4% albumin
Number of subjects: 34
Study: 16435076

Group type: EXPERIMENTAL
Intervention: Bisphosphonate therapy (10 mg alendronate or 5 mg risedronate) with calcium/vitamin D
Number of subjects: 56

Group type: COMPARATOR
Intervention: Calcium/vitamin D treatment alone (control group)
Number of subjects: 56
Study: 14984232

Group type: EXPERIMENTAL
Intervention: Prednisone (60 mg/day for 2 days, 40 mg/day for 2 days, and 20 mg/day for 2 days) for 6 days
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Naratriptan (2.5 mg twice a day) during the initial period
Number of subjects: 150

Group type: COMPARATOR
Intervention: Nothing (no regular medications) during the initial period
Number of subjects: 150
Study: 10858975

Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg orally for 14 to 21 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8976635

Group type: EXPERIMENTAL
Intervention: Intensive dynamic group exercises (full weight bearing and conditioning exercises on a stationary bicycle at 70-85% of age predicted maximum heart rate)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Range of motion (ROM) exercises and isometric exercises
Number of subjects: 100

Group type: COMPARATOR
Intervention: Individual isometric and ROM exercises
Number of subjects: 100

Group type: COMPARATOR
Intervention: Home instructions for isometric and ROM exercises
Number of subjects: 100
Study: 1467613

Group type: EXPERIMENTAL
Intervention: Budesonide 200 micrograms bid
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 6367406

Group type: EXPERIMENTAL
Intervention: Diltiazem (120 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propranolol (100 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30053843

Group type: EXPERIMENTAL
Intervention: Adherence Rating Scale (ARS) based on exercise therapy adherence prediction model.
Number of subjects: 218
Study: 27633621

Group type: EXPERIMENTAL
Intervention: School-based intervention including teacher training, opportunities for PA, and health education.
Number of subjects: 548
Study: 24912491

Group type: EXPERIMENTAL
Intervention: Methylphenidate (intravenous)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Methylphenidate with cocaine cue-video
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Methylphenidate with neutral-video
Number of subjects: 62
Study: 22962431

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 61

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 61
Study: 20434071

Group type: EXPERIMENTAL
Intervention: Dried prunes preload
Number of subjects: 45

Group type: COMPARATOR
Intervention: Bread product preload
Number of subjects: 45
Study: 18581129

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection
Number of subjects: 23
Study: 15837450

Group type: EXPERIMENTAL
Intervention: Active intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active intervention and Placebo
Number of subjects: 0
Study: 12006904

Group type: EXPERIMENTAL
Intervention: Quinidine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 10541942

Group type: EXPERIMENTAL
Intervention: PEEP at 3 cmH(2)O
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: PEEP at 6 cmH(2)O
Number of subjects: 8

Group type: COMPARATOR
Intervention: PEEP at 0 cmH(2)O
Number of subjects: 8
Study: 7802520

Group type: EXPERIMENTAL
Intervention: Lipid lowering treatment
Number of subjects: 36000

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 36000
Study: 2225715

Group type: EXPERIMENTAL
Intervention: Caffeine 250 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7352849

Group type: EXPERIMENTAL
Intervention: Therapeutic community (more than seven weeks)
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Methadone maintenance
Number of subjects: 585

Group type: COMPARATOR
Intervention: Therapeutic community (less than seven weeks)
Number of subjects: 585

Group type: COMPARATOR
Intervention: No treatment beyond short detoxification
Number of subjects: 585
Study: 31479022

Group type: EXPERIMENTAL
Intervention: Dynamic retinoscopy
Number of subjects: 95

Group type: COMPARATOR
Intervention: Open-field autorefraction
Number of subjects: 95
Study: 27670644

Group type: EXPERIMENTAL
Intervention: Multifunctional diet (MFD)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control diet devoid of the active components of MFD
Number of subjects: 44
Study: 25967707

Group type: EXPERIMENTAL
Intervention: Low-nitrogen and low-calorie parenteral nutrition combined with enteral nutrition (EN)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 90
Study: 24037015

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Oral Appliance
Number of subjects: 25

Group type: COMPARATOR
Intervention: Physical Exercise
Number of subjects: 25
Study: 22433704

Group type: EXPERIMENTAL
Intervention: Ingavirin combined with an antibacterial agent
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study: 19673928

Group type: EXPERIMENTAL
Intervention: Prolonged-release (PR) torasemide 5 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Prolonged-release (PR) torasemide 10 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Immediate-release (IR) torasemide 5 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Immediate-release (IR) torasemide 10 mg
Number of subjects: 20
Study: 17061421

Group type: EXPERIMENTAL
Intervention: DBM putty composite (n = 10)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Iliac crest autograft (n = 8)
Number of subjects: 18
Study: 15089807

Group type: EXPERIMENTAL
Intervention: 0.25 mg kg(‐1) ephedrine sulphate
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 0.5 mg kg(‐1) ephedrine sulphate
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 1.0 mg kg(‐1) ephedrine sulphate
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 11263615

Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study: 9626213

Group type: EXPERIMENTAL
Intervention: Cisplatin 80 mg/m2 + Teniposide 100 mg/m2 (arm A)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m2 (arm B)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Cisplatin + Teniposide (arm A)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Paclitaxel (arm B)
Number of subjects: 332
Study: 7923659

Group type: EXPERIMENTAL
Intervention: c7E3 Fab (0.25 mg/kg bolus dose)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: c7E3 Fab (continuous infusion for up to 24 hours)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: c7E3 Fab
Number of subjects: 56
Study: 3197915

Group type: EXPERIMENTAL
Intervention: Ampicillin suppository
Number of subjects: 683

Group type: COMPARATOR
Intervention: Amoxycillin suspension
Number of subjects: 683
Study: 31079517

Group type: EXPERIMENTAL
Intervention: Lifestyle program with periodic group-based activities on healthy lifestyle behaviors
Number of subjects: 1903

Group type: COMPARATOR
Intervention: One-time education program (control)
Number of subjects: 1903
Study: 28241991

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (two 250‐mg tablets of magnesium oxide daily for 8 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (two tablets daily for 8 weeks)
Number of subjects: 60
Study: 25727810

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (2000‐4000 IU cholecalciferol) orally daily until delivery
Number of subjects: 78

Group type: COMPARATOR
Intervention: No supplementation
Number of subjects: 78
Study: 23595385

Group type: EXPERIMENTAL
Intervention: Total Lumbar Disc Replacement (TDR)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Traditional fixation procedure (control)
Number of subjects: 68
Study: 21345714

Group type: EXPERIMENTAL
Intervention: Baseline neck pain measured using the Northwick Park Neck Pain Questionnaire (NPQ)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Baseline upper limb disability measured using the Disabilities of Arm, Shoulder, Hand questionnaire (DASH)
Number of subjects: 151
Study: 19837094

Group type: EXPERIMENTAL
Intervention: Cholera vaccine alone
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Cholera vaccine plus zinc supplementation
Number of subjects: 3

Group type: COMPARATOR
Intervention: Zinc alone
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Cholera vaccine with zinc supplementation
Number of subjects: 3
Study: 16476596

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced Duplex ultrasonography
Number of subjects: 20

Group type: COMPARATOR
Intervention: CT angiography (CTA)
Number of subjects: 20
Study: 15185303

Group type: EXPERIMENTAL
Intervention: Endoscopic Injection Sclerotherapy (EIS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Endoscopic Band Ligation (EBL)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both EIS and EBL
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Initial HVPG greater than 16 mm Hg
Number of subjects: 50
Study: 11499184

Group type: EXPERIMENTAL
Intervention: Oral misoprostol (50 micrograms)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravaginal prostaglandin E2 (4 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravaginal prostaglandin E2
Number of subjects: 60
Study: 9571345

Group type: EXPERIMENTAL
Intervention: Intensive treatment arm aiming for normal HbA1c levels
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Phase I: evening intermediate or long-acting insulin
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Phase II: added daytime glipizide (up to 10 mg/day)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Phase III: two injections of insulin alone
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Phase IV: multiple daily insulin injections
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Combination of glipizide and insulin (up to 20 mg/day)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Home glucose monitoring
Number of subjects: 153
Study: 7835326

Group type: EXPERIMENTAL
Intervention: High intensity exercise
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Long duration high intensity exercise
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control
Number of subjects: 23
Study: 2896425

Group type: EXPERIMENTAL
Intervention: 10% phenylephrine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.5% thymoxamine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.5% thymoxamine + 10% phenylephrine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 3% isoproterenol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.5% timolol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.5% betaxolol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low-luminance myopia
Number of subjects: 10
Study: 30375382

Group type: EXPERIMENTAL
Intervention: Carbapenem hydrolysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Penicillin hydrolysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cephalosporin hydrolysis
Number of subjects: 0
Study: 26851605

Group type: EXPERIMENTAL
Intervention: Experimental intervention (ten face-to-face educational sessions)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Minimal control intervention (mailed information)
Number of subjects: 150
Study: 25586759

Group type: EXPERIMENTAL
Intervention: Interspinous process devices (IPD)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Bony decompression
Number of subjects: 159
Study: 24021517

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (100 μg twice weekly) with cyclic progesterone
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo patches and pills
Number of subjects: 72
Study: 20869812

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 642

Group type: COMPARATOR
Intervention: Nicotine lozenge
Number of subjects: 642
Study: 18372276

Group type: EXPERIMENTAL
Intervention: Warfarin for long-term secondary prevention of VTE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unfractionated and low-molecular-weight heparins for primary prophylaxis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk assessment for prophylaxis decision-making
Number of subjects: 0
Study: 12352277

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment (sertraline, desipramine)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 46
Study: 9583291

Group type: EXPERIMENTAL
Intervention: Endothelial cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mitogens concanavalin‐A and phytohaemagglutinin‐P
Number of subjects: 0
Study: 8126147

Group type: EXPERIMENTAL
Intervention: Acipimox (125 mg, 12 times/24 h)
Number of subjects: 8
Study: 2768614

Group type: EXPERIMENTAL
Intervention: Problem-solving skills training (PSST)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Problem-solving skills training with in vivo practice (PSST-P)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Client-centered relationship therapy (RT)
Number of subjects: 112
Study: 886043

Group type: EXPERIMENTAL
Intervention: Acupuncture-positive milieu
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Acupuncture-negative milieu
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo acupuncture-positive milieu
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo acupuncture-negative milieu
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Acupuncture and placebo acupuncture
Number of subjects: 42
Study: 31840815

Group type: EXPERIMENTAL
Intervention: SIRT + FOLFOX
Number of subjects: 1103

Group type: COMPARATOR
Intervention: FOLFOX alone
Number of subjects: 1103
Study: 27862950

Group type: EXPERIMENTAL
Intervention: Transdermal 17β‐oestradiol (E2) 0.15 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 25819860

Group type: EXPERIMENTAL
Intervention: Apixaban 5.0 mg twice daily
Number of subjects: 2995

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2995
Study: 23594968

Group type: EXPERIMENTAL
Intervention: 60 mg loading dose of prasugrel
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 30 mg loading dose of prasugrel
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 10 mg maintenance dose of prasugrel
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 7.5 mg maintenance dose of prasugrel
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 5 mg maintenance dose of prasugrel
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Daily 5 mg doses of prasugrel
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 10 mg, 7.5 mg, and 5 mg doses of prasugrel
Number of subjects: 30
Study: 20494865

Group type: EXPERIMENTAL
Intervention: Mimicry (imitation of nonverbal behavior)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonmimicry (control group)
Number of subjects: 0
Study: 19559143

Group type: EXPERIMENTAL
Intervention: Hand-held personal digital assistant (PDA)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Traditional written records
Number of subjects: 26
Study: 16636528

Group type: EXPERIMENTAL
Intervention: Group 1 (performing a second and a third PR after 6 and 12 months)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Group 2 (performing only a second PR after 12 months)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Group 1
Number of subjects: 35
Study: 16259438

Group type: EXPERIMENTAL
Intervention: Bestim
Number of subjects: 0
Study: 11329784

Group type: EXPERIMENTAL
Intervention: 5'‐DFUR + LV (leucovorin)
Number of subjects: 62

Group type: COMPARATOR
Intervention: 5'‐DFUR alone
Number of subjects: 62
Study: 9209661

Group type: EXPERIMENTAL
Intervention: Five courses of carboplatin 400 mg/m2 or cisplatin 75 mg/m2
Number of subjects: 225

Group type: COMPARATOR
Intervention: Eight courses of carboplatin 400 mg/m2 or cisplatin 75 mg/m2
Number of subjects: 225
Study: 8429800

Group type: EXPERIMENTAL
Intervention: Combined therapy (2 mg oestradiol (E2) and 1 mg norethisterone acetate (NETA) daily)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Sequential therapy (2 mg E2 for 12 days, 2 mg E2 and 1 mg NETA for 10 days, and 1 mg E2 for 6 days)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 29984601

Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27742464

Group type: EXPERIMENTAL
Intervention: IRB300 + ATO40
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: IRB300 + ATO80
Number of subjects: 230

Group type: COMPARATOR
Intervention: ATO40
Number of subjects: 230

Group type: COMPARATOR
Intervention: ATO80
Number of subjects: 230

Group type: COMPARATOR
Intervention: IRB300
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 230
Study: 25361615

Group type: EXPERIMENTAL
Intervention: Unfiltered rides (exposed to TRAPs)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Filtered rides (not exposed to TRAPs)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Particle number concentration increase
Number of subjects: 21
Study: 22525910

Group type: EXPERIMENTAL
Intervention: Nomegestrol acetate (2.5 mg) and 17β‐E2 (1.5 mg) in a 24‐4‐day regimen
Number of subjects: 2281

Group type: COMPARATOR
Intervention: Drospirenone (3.0 mg) and ethinyl E2 (30 micrograms) in a 21‐7‐day regimen
Number of subjects: 2281
Study: 20443094

Group type: EXPERIMENTAL
Intervention: FAST (weight loss > or = 0.68 kg/week, n = 69)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: MODERATE (weight loss > or = 0.23 and < 0.68 kg/week, n = 104)
Number of subjects: 262

Group type: COMPARATOR
Intervention: SLOW (weight loss < 0.23 kg/week, n = 89)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: FAST and MODERATE groups
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 262
Study: 20635912

Group type: EXPERIMENTAL
Intervention: Immunotherapy with heat-killed Mycobacterium vaccae (SRL172)
Number of subjects: 0
Study: 16856574

Group type: COMPARATOR
Intervention: Epidural spinal cord stimulation (SCS)
Number of subjects: 18
Study: 12538037

Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Leuprorelin acetate depot
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (women without endometriosis)
Number of subjects: 48
Study: 10868467

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Divalproex
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9083239

Group type: EXPERIMENTAL
Intervention: Albumin 4% + hydroxyethylstarch 6%
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Albumin 4% + dextran 40
Number of subjects: 27

Group type: COMPARATOR
Intervention: Albumin 4% alone
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Albumin 4% + hydroxyethylstarch 6% or dextran 40
Number of subjects: 27
Study: 8410927

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg twice daily)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg once daily)
Number of subjects: 13
Study: 3739820

Group type: EXPERIMENTAL
Intervention: High dose of nicotine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low dose of nicotine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not smoking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonsmokers
Number of subjects: 0
Study: 31390314

Group type: COMPARATOR
Intervention: Sandblasting (50 μm alumina particles)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Laser irradiation at 2 W
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Laser irradiation at 1 W
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Laser irradiation at 3 W
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 50
Study: 29923910

Group type: EXPERIMENTAL
Intervention: Hypoxic exercise training (FiO2 15%)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normoxic exercise training
Number of subjects: 14
Study: 26844926

Group type: EXPERIMENTAL
Intervention: Inhaled allergen
Number of subjects: 0
Study: 25227477

Group type: EXPERIMENTAL
Intervention: Music therapy during labor
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 156
Study: 22456770

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 23

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 23
Study: 20332142

Group type: EXPERIMENTAL
Intervention: Temsirolimus (25 mg)
Number of subjects: 626

Group type: COMPARATOR
Intervention: Temsirolimus (15 mg) + IFN-alpha
Number of subjects: 626

Group type: COMPARATOR
Intervention: IFN-alpha
Number of subjects: 626